Name: 2H-1,4-BENZODIAZEPIN-2-ONE, 7-CHLORO-1-(CYCLOPROPYLMETHYL)-5-(2-FLUOROPHENYL)-1,3-DIHYDRO-
SKU: 25967-29-7

Products Categories

Pharmaceutical (45)
Others (10)
Organic Chemicals (4)
Reagent (1)
Materials (1)

Basic Information

Molecular Structure:
CAS No.:	25967-29-7
Name:	2H-1,4-BENZODIAZEPIN-2-ONE, 7-CHLORO-1-(CYCLOPROPYLMETHYL)-5-(2-FLUOROPHENYL)-1,3-DIHYDRO-
Article Data:	6

Formula:	C₁₉H₁₆ClFN₂O
Molecular Weight:	342.8
Synonyms:	2H-1,4-Benzodiazepin-2-one,7-chloro-1-(cyclopropylmethyl)-5-(o-fluorophenyl)-1,3-dihydro- (8CI);1-Cyclopropylmethyl-5-(o-fluorophenyl)-7-chloro-1,3-dihydro-2H-1,4-benzodiazepine-2-one;Flutoprazepam;ID 1937;KB 509;Restar;Restas;
Density:	1.37g/cm³
Melting Point:	118-122°
Boiling Point:	539.3 °C at 760 mmHg
Flash Point:	279.9 °C
PSA:	32.67000
LogP:	3.57370

Country:
Business Type:
All

Lab/Research institutions

Trading Company

Manufacturers

Other
Certificate:
Manufacturer

Enterprise Authentication

ISO

GMP

FDA

HALAL

Display:default sort
Suppiers of more reward points first

New supplier

Total:57 Page 1 of 2 1 2 Next>>

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 25967-29-7

Specification

The Flutoprazepam ,its cas register number is 25967-29-7. IUPAC name about this chemicals is 7-chloro-1-(cyclopropylmethyl)-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one . Following are the physical and chemical properties about it: (1)Index of Refraction: 1.661 ; (2)Molar Refractivity: 92.24 cm³ ; (3)Molar Volume: 249.3 cm³ ; (4)Surface Tension: 48.2 dyne/cm ; (5) Enthalpy of Vaporization: 81.66 kJ/mol ; (6)Vapour Pressure: 1.07E-11 mmHg at 25°C . Classification code about it are Drug / Therapeutic Agent and Reproductive Effect .

The Flutoprazepam is a drug which is a benzodiazepine derivative. this chemicals was invented in Japan in 1972, and its medical use remains mostly confined to that country. Its muscle relaxant properties are approximately equivalent to those of diazepam - however, it has more powerful sedative, hypnotic, anxiolytic and anticonvulsant effects and is around four times more potent by weight compared to diazepam. It is longer acting than diazepam due to its long-acting active metabolites, which contribute significantly to its effects. Also it can be typically used for the treatment of severe insomnia and may also be used for treating stomach ulcers.

Abuse of benzodiazepines in Japan is extremely common, flutoprazepam is being one of the most commonly abused, along with the benzodiazepines of abuse nimetazepam, temazepam and triazolam.This chemicals is currently a Schedule IV drug under the international Convention on Psychotropic Substances of 1971. In Singapore, it is a Class C-Schedule II drug under the Misuse of Drugs Act. Also in Hong Kong, flutoprazepam is regulated under Schedule 2 of Hong Kong's Chapter 134 Dangerous Drugs Ordinance. It may be prescribed for the treatment of insomnia by a registered medical doctor. The penalty for trafficking or manufacturing the substance is a $100,000 (HKD) fine and possibly a short imprisonment (1-2 years). Possession of the substance for consumption without valid prescription from a registered medical doctor is illegal and punishable with a $50,000 (HKD) fine.

This chemicals can be described computed from structure:
1) Canonical SMILES: C1CC1CN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4F
2) InChI: InChI=1S/C19H16ClFN2O/c20-13-7-8-17-15(9-13)19(14-3-1-2-4-16(14)21)22-10-18(24)23(17)11-12-5-6-12/h1-4,7-9,12H,5-6,10-11H2
3) InChIKey: OFVXPDXXVSGEPX-UHFFFAOYSA-N

The most important thing about Flutoprazepam is the toxicity, following is the form:

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
dog	LD50	oral	> 10gm/kg (10000mg/kg)	SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) GASTROINTESTINAL: NAUSEA OR VOMITING	Oyo Yakuri. Pharmacometrics. Vol. 20, Pg. 1005, 1980.
monkey	LD50	oral	> 4gm/kg (4000mg/kg)	GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS GASTROINTESTINAL: NAUSEA OR VOMITING	Oyo Yakuri. Pharmacometrics. Vol. 20, Pg. 1005, 1980.
mouse	LD50	intraperitoneal	2110mg/kg (2110mg/kg)	BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) BEHAVIORAL: ATAXIA	Oyo Yakuri. Pharmacometrics. Vol. 20, Pg. 1055, 1980.
mouse	LD50	oral	2430mg/kg (2430mg/kg)	BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) BEHAVIORAL: ATAXIA	Oyo Yakuri. Pharmacometrics. Vol. 20, Pg. 1055, 1980.
mouse	LD50	subcutaneous	> 5gm/kg (5000mg/kg)	BEHAVIORAL: MUSCLE WEAKNESS BEHAVIORAL: ATAXIA	Oyo Yakuri. Pharmacometrics. Vol. 20, Pg. 1005, 1980.
rabbit	LD50	oral	1gm/kg (1000mg/kg)	BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) BEHAVIORAL: ATAXIA	Oyo Yakuri. Pharmacometrics. Vol. 20, Pg. 1055, 1980.
rat	LD50	intraperitoneal	2230mg/kg (2230mg/kg)	BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) BEHAVIORAL: ATAXIA	Oyo Yakuri. Pharmacometrics. Vol. 20, Pg. 1055, 1980.
rat	LD50	oral	10060mg/kg (10060mg/kg)	BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) BEHAVIORAL: ATAXIA	Oyo Yakuri. Pharmacometrics. Vol. 20, Pg. 1055, 1980.
rat	LD50	subcutaneous	> 5gm/kg (5000mg/kg)	BEHAVIORAL: MUSCLE WEAKNESS BEHAVIORAL: ATAXIA	Oyo Yakuri. Pharmacometrics. Vol. 20, Pg. 1005, 1980.